Medical cannabis company Kanabo has moved its CBD-based smoking cessation formula one step closer to full patent approval and called on the MHRA to implement regulation around hemp CBD inhalation.
Kanabo has announced that its unique CBD and nicotine formula has moved from the Patent Cooperation Treaty (PCT) phase to the National Phase in the US, UK, and EU countries. This phase is the last before becoming an internationally approved patent.
The unique CBD formulation has been developed for individuals that want to quit their smoking habit. The high potency CBD and nicotine, and standalone CBD formulas, are delivered by Kanabo’s proprietary cartridges and VapePod – which is the world’s first medical-grade vapouriser.
The news comes as governments around the world move to end people’s addiction to nicotine products. This includes New Zealand, which recently announced it would be banning the sale of nicotine to anyone born after 2008, and the UK – which recently announced the Medicines and Healthcare products Regulatory Agency (MHRA) will be supporting the NHS in prescribing e-cigarettes as licensed therapies to help patients quit smoking.
Kanabo CEO, Avihu Tamir, commented: “Our unique patent pending CBD formulations and controlled and consistent delivery device, the VapePod, represents an excellent opportunity for governments to quickly end the reliance on tobacco for millions of citizens worldwide.
“Our tests show a dramatic reduction in nicotine consumption, whether in cigarettes or e-cigarettes, which can only be good news for health services around the world.”
Covered under the patent application is the unique formula development of specific naturally derived terpenes to allow the application of a consistent and reproducible, high concentration of CBD throughout the life of the cartridge.
It works by initially combining CBD with nicotine, which is then reduced over several weeks until there is zero nicotine presence.
The company has carried out tests with a number of volunteers who smoke. The trial presented an average reduction of 70 per cent in the participants cigarette consumption. Kanabo has said that, so far, evidence has suggested that the programme significantly reduces physical and psychological withdrawal effects.
Kanabo recently welcomed the UK’s announcement regarding e-cigarettes, which was a response to the Government’s Tobacco Control Plan.
Under the new guidance for approved e-cigarettes, products would need to meet the standards of quality, safety, and efficacy expected of medicinal products to achieve a licence. The MHRA has invited manufacturers to submit products to undergo the same approval process as prescribed medicines.
“Any research that helps patients has to be welcomed. Kanabo started its commercial life by addressing the issue of developing a device to deliver a reliable and repeatable metered dose of medicinal cannabis to help patients combat their ailments,” said Tamir.
“The Company’s proprietary VapePod is now a class-leading medical device available in the UK. As the UK’s regulatory framework outlines a higher entry barrier for the industry, the global vaping industry will witness a more standardised and concentrated market where industry leaders, such as Kanabo, will further strengthen their leading positions.
“Meanwhile, the whole industry, the supply chain and patients will benefit from such a well-regulated and standardised market in turn.”
Kanabo has now called for regulation of CBD inhalation, stating: “We are calling on the MHRA to set a regulation for hemp CBD inhalation. There needs to be regulation to set a standard”
[activecampaign form=31]
